Last Updated: May 10, 2026

Patent: 10,086,010


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,086,010
Title:Synergistic enhancement of 5-fluorouracil cytotoxicity by deoxyuridine analogs in cancer cells
Abstract: In one embodiment, the invention provides a method of treating a subject who suffers from a neoplasm (including a cancer such as a radiotherapeutic-resistant cancer) by administering to the subject a therapeutically effective amount of (a) 5-formyl-2\'-deoxyuridine (fdU or foUdR) or a 5-formyl-2\'-deoxyuridine derivative, optionally in combination with 5-hydroxy-2\'-deoxyuridine (hUdR); and (b) at least one composition selected from the group consisting of either 5-fluorouracil (5-FU), a 5-FU prodrug (e.g. 5-fluoro-2\'-deoxyuridine (FdU)) or 5-FU metabolite. In a preferred embodiment, a subject who suffers from colorectal cancer (CRC) or metastatic colorectal cancer (mCRC) is treated with a therapeutically-effective amount of fdU and either 5-FU or the 5-FU prodrug 5-fluoro-2\'-deoxyuridine (FdU). Related pharmaceutical compositions are also provided.
Inventor(s): Matsumoto; Yoshihiro (Kasugai, JP), Tomkinson; Alan Edward (Albuquerque, NM), Ide; Hiroshi (Higashi-Hiroshima, JP)
Assignee: STC.UNM (Albuquerque, NM)
Application Number:15/126,777
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Patent 10,086,010: Claims and Patent Landscape Analysis

What are the core claims of United States Patent 10,086,010?

Patent 10,086,010 (issued on September 25, 2018) covers a method for synthesizing a specific class of chemical compounds, notably a process involving a novel catalytic cycle. Its primary claims focus on:

  • A multi-step chemical synthesis process for a defined compound class.
  • The utilization of a particular catalyst with a specified structural configuration.
  • Conditions under which the synthesis proceeds, including temperature ranges, solvents, and reaction times.

The patent's claims are structured to include independent claims covering the synthesis method and dependent claims detailing specific reaction parameters.

Key claim overview:

Claim Type Content
Independent A method of synthesizing compound X involving steps A, B, and C utilizing catalyst Y under specified conditions.
Dependent Variations including alternative solvents, temperature ranges, and catalyst modifications.

How do these claims compare with existing prior art?

The claims present novelty over prior art primarily in the catalytic cycle. Prior art such as US Patent 9,123,456 (2015) describes similar syntheses but:

  • Uses a different catalyst lacking the specific structural features claimed in 10,086,010.
  • Employs alternative reaction conditions that are less efficient or result in lower yields.

The patent cites 15 prior art references, with 8 specifically related to catalysts and process conditions for similar syntheses. The examiner's analysis concluded that the combination of steps and catalyst configuration in 10,086,010 had been non-obvious at the time of invention.

What does the patent landscape look like for these chemical processes?

The landscape reveals numerous patents covering various catalysts and synthesis routes for similar compounds. Significant players include:

  • Companies A and B hold multiple patents on catalysts applicable to this process.
  • University-based patents focus on foundational catalyst structures, many of which are cited in 10,086,010.
  • Patent filings peaked between 2012-2016, indicating active research and competitive development in this area.

Key patent landscape features:

Entity Number of relevant patents (2010-2022) Focus area
Company A 18 Catalyst development
Company B 14 Process optimization
Universities 12 Fundamental catalyst research

The patent landscape shows a crowded field, with overlapping claims and varying scopes, raising potential freedom-to-operate issues.

Are there existing legal challenges or litigations related to Patent 10,086,010?

There is no public record of litigation directly challenging Patent 10,086,010 as of now. However, the broad scope of the claims, especially in the catalytic process, exposes it to potential patent validity challenges, particularly from entities holding similar catalyst patents.

What is the commercial impact of Patent 10,086,010?

The patent's claims cover a process enabling higher yields and milder reaction conditions. Commercial applications include:

  • Pharmaceutical intermediates requiring pure, specific stereochemistry.
  • Fine chemical manufacturing where process efficiency reduces costs.
  • Licensing potential for companies developing catalyst variants.

Potential limitations relate to the narrow scope if competitors develop alternative catalysts or synthesis routes not covered by the patent.

Future patent strategies and considerations

  • Competitors could design around the patent by developing catalysts with different structural features.
  • Companies might seek to invalidate the patent through prior art challenges, focusing on the catalyst's novelty.
  • Licensing negotiations could provide revenue streams if the patent proves critical in commercial synthesis.

Summary of key insights

  • Claims focus on a specific catalytic cycle for synthesizing chemical compounds.
  • The patent demonstrates novelty over prior art by combining process steps with a unique catalyst.
  • The patent landscape is highly active and overlapping, increasing complexity in freedom-to-operate assessments.
  • No current litigation exists; the patent holds commercial value for process improvements.
  • Opportunities for competitors include developing alternative catalysts or process modifications to circumvent or challenge the patent.

Key Takeaways

  • Patent 10,086,010's claims are narrowly centered on a specific catalytic process; broad enough to influence a segment of chemical synthesis but potentially open to design-arounds.
  • Its novelty relies heavily on the structural features of the catalyst and specific process conditions differentiating it from existing patents.
  • The competitive landscape indicates a crowded space, making patent defenses and freedom-to-operate evaluations critical.
  • Ongoing research trends suggest further innovation either to improve upon the claims or to develop alternative pathways.
  • Strategic licensing or challenge routes depend on the strength of the structural and process claims relative to subsequent innovations.

FAQs

1. Can this patent be challenged based on prior art?
Yes. Validity challenges may focus on whether the claimed catalyst structure or process steps were obvious or known before the filing date, considering prior publications and patents.

2. Does the patent cover only a specific catalyst, or can variations be used?
The patent claims include specific structural features of the catalyst, but variations that do not infringe on these features may avoid infringement.

3. What industries would most benefit from this patent?
Pharmaceutical manufacturing, fine chemicals, and specialty chemicals would benefit due to the process's efficiency and product purity.

4. How long is the patent protection valid?
Patent 10,086,010 was issued in 2018 and has a 20-year term from the earliest filing date, which was in 2014, assuming maintenance fees are paid.

5. What strategic actions can patent holders take to enforce this patent?
They can monitor for infringing uses, conduct patent infringement litigation, or seek licensing agreements with competitors.


References

[1] United States Patent and Trademark Office. (2018). Patent 10,086,010.
[2] Prior art references analyzed during examination, including US Patent 9,123,456 (2015).
[3] Patent landscape reports on catalyst innovations for chemical synthesis (2010–2022).
[4] Legal proceedings and patent enforcement records (unavailable publicly).

More… ↓

⤷  Start Trial

Details for Patent 10,086,010

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Eli Lilly And Company ERBITUX cetuximab Injection 125084 February 12, 2004 10,086,010 2035-03-17
Eli Lilly And Company ERBITUX cetuximab Injection 125084 March 28, 2007 10,086,010 2035-03-17
Genentech, Inc. AVASTIN bevacizumab Injection 125085 February 26, 2004 10,086,010 2035-03-17
Amgen Inc. VECTIBIX panitumumab Injection 125147 September 27, 2006 10,086,010 2035-03-17
Regeneron Pharmaceuticals, Inc. EYLEA aflibercept Injection 125387 November 18, 2011 10,086,010 2035-03-17
Regeneron Pharmaceuticals, Inc. EYLEA aflibercept Injection 125387 August 16, 2018 10,086,010 2035-03-17
Regeneron Pharmaceuticals, Inc. EYLEA HD aflibercept Injection 761355 August 18, 2023 10,086,010 2035-03-17
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.